CIRBP Protein Identified as Multiple Myeloma Suppressor
Researchers discovered that boosting this protein could potentially curb the growth of multiple myeloma cancer cells.
Updated on Sept. 22, 2026 in Cancer
Scientists have identified the CIRBP protein as a potential tumor suppressor in multiple myeloma patients, where its expression is often found to be decreased. By restoring CIRBP levels, researchers successfully inhibited the proliferation of cancer cells in preliminary laboratory models.
Why it matters
This finding identifies a new potential molecular target that could influence how researchers approach stopping cancer cell growth and managing tumor burden in those diagnosed with multiple myeloma.
In a preclinical study using human multiple myeloma cell lines and xenograft models, researchers found that increasing CIRBP expression inhibited cell viability and tumor growth. The findings are preliminary, as the mechanism has not yet been tested in human subjects.
The players
Nature Communications
The scientific journal that published this peer-reviewed research.
The details
The protein CIRBP functions by binding to the intron1 region of PKM2 pre-mRNA, which inhibits the splicing of this gene and promotes its decay. By downregulating PKM2, CIRBP also suppresses the specific macrophage activation and chemotaxis that cancer cells often exploit to thrive. These cellular changes combined to reduce the overall tumor burden in the study's experimental models.
Timeline
September 22, 2026: The research findings were published.
Health Landscape
This study advances the field of oncology by linking the protein CIRBP to the well-studied PKM2 metabolic pathway in cancer development. It contributes to a growing body of work exploring how RNA-binding proteins can be leveraged to suppress tumor activity.
This development is a preclinical finding and does not change current treatment protocols or medical care. Patients with questions about the biology of their specific diagnosis should consult with their oncology team to understand the factors driving their condition.
The takeaway
The study suggests that the CIRBP protein acts as a natural brake on multiple myeloma growth by regulating cellular metabolism. Staying informed about the underlying biological drivers of a diagnosis is a helpful way to prepare for future conversations with your oncology specialist.
Further reading
For more on the current strategies being explored in the lab, visit the Cancer section.
More information
Read the complete peer-reviewed research article in Nature Communications.
Source note: This article includes information reported by Nature.
